Genentech Reports P-III Study (COMMODORE 2) Results of Crovalimab for Paroxysmal Nocturnal Hemoglobinuria
Shots:
- The P-III study (COMMODORE 2) evaluating crovalimab (SC, q4w) vs eculizumab (IV, q2w) in a ratio (2:1) in PNH patients who have not been prior treated with complement inhibitors
- The study met its co-primary efficacy EPs of transfusion avoidance & control of hemolysis & patients achieved disease control & were non-inferior to eculizumab. The P-III study (COMMODORE 1) results in PNH patients switching from currently approved C5 inhibitors also supported the favorable benefit-risk profile of crovalimab (anti-C5 recycling mAb) as reported in (COMMODORE 2) study
- Both studies' results will be submitted to regulatory authorities globally. The therapy is being studied in a clinical development program incl. 5 ongoing P-III studies
Ref: Businesswire | Image: Genentech
Related News:- Genentech Reports P-III Study (IMbrave050) Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) for Early-Stage Liver Cancer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
